MIT Libraries | DSpace@MIT

MIT Open Access Articles

An Exported Peptide Functions Intracellularly to Contribute to Cell Density Signaling in B. subtilis

Massachusetts Institute of Technology

An Exported Peptide Functions Intracellularly to Contribute to Cell Density Signaling in B. subtilis

Beth A. Lazazzera, Jonathan M. Solomon,*
and Alan D. Grossman
Department of Biology
Massachusetts Institute of Technology
Cambridge, Massachusetts 02139

Summary

Competence development and sporulation in B. subtilis are partly controlled by peptides that accumulate in culture medium as cells grow to high density. We constructed two genes that encode mature forms of two different signaling molecules, the PhrA peptide that stimulates sporulation, and CSF, the competence- and sporulation-stimulating factor. Both pentapeptides are normally produced by secretion and processing of precursor molecules. The mature pentapeptides were functional when expressed inside the cell, indicating that they normally need to be imported to function. Furthermore, at physiological concentrations (10 nM), CSF was transported into the cell by the oligopeptide permease encoded by spo0K (opp). CSF was shown to have at least three different targets corresponding to its three activities: stimulating competence gene expression at low concentrations, and inhibiting competence gene expression and stimulating sporulation at high concentrations.

Introduction

In bacteria, the ability to sense and respond to high population density, a trait common to many organisms, is often referred to as quorum sensing (Fuqua et al., 1996). In Bacillus subtilis, several peptide factors function in quorum sensing, and these factors contribute, in part, to the regulation of two different developmental pathways. The initiation of sporulation (Stragier and Losick, 1996) and the development of genetic competence (the natural ability to bind and take up exogenous DNA [Solomon and Grossman, 1996]) are most efficient in cells at high culture density (Grossman, 1995).

The competence and sporulation stimulating factor, CSF, is one of the extracellular peptide factors from B. subtilis that functions in quorum sensing. CSF is an unmodified pentapeptide that corresponds to the C-terminal 5 amino acids of the 40 amino acid polypeptide encoded by phrC (Solomon et al., 1996). CSF was purified from cell-free culture supernatant based on its ability to stimulate transcription from an early competence promoter (srfA) in cells at low cell density (Solomon et al., 1996).

Transcription of srfA is directly activated by the phosphorylated form of the transcription factor, ComA (Nakano and Zuber, 1989, 1991; Weinrauch et al., 1989; Nakano et al., 1991; Roggiani and Dubnau, 1993). ComA

is phosphorylated on an aspartate residue in the N-terminal regulatory domain, typical of the response regulator family of proteins (Parkinson and Kofoid, 1992; Hoch and Silhavy, 1995). Phosphorylation of ComA is controlled primarily by ComP, a membrane-bound histidine protein kinase that autophosphorylates on a histidine residue and donates phosphate to ComA (Weinrauch et al., 1990). Transcription of the srfA operon increases as cells grow to high density due to accumulation of CSF and a second extracellular signaling factor, the ComX pheromone, a modified 10 amino acid peptide (Magnuson et al., 1994; Solomon et al., 1995, 1996).

Both CSF and the ComX pheromone stimulate transcription of srfA by increasing the concentration of phosphorylated ComA. The ComX pheromone stimulates activity of the kinase, ComP (Solomon et al., 1995), while CSF probably inhibits (either directly or indirectly) activity of RapC, a protein homologous to response regulator aspartyl phosphate phosphatases.

CSF has at least three activities. At low concentrations (1–10 nM), CSF stimulates expression of srfA, probably by inhibiting activity of the RapC phosphatase. At higher concentrations (20 nM–1 μM), CSF inhibits expression of srfA, by a mechanism that is independent of rapC. High concentrations of CSF also stimulate sporulation (Solomon et al., 1996). These responses to extracellular CSF depend on the spo0K (opp)-encoded oligopeptide permease (Solomon et al., 1995, 1996), a member of the ATP-binding cassette (ABC) transporter family (Perego et al., 1991; Rudner et al., 1991). Several ABC transporters in bacteria have dual roles, one in transport and a second as a receptor in signaling (Manson et al., 1986; Cox et al., 1988; Cangelosi et al., 1990; Wanner, 1993), raising the possibility that the oligopeptide permease may be functioning as a receptor for response to CSF.

phrC, encoding the precursor of CSF, is a member of a family of at least four B. subtilis genes thought to encode precursors of signaling peptides (Perego et al., 1996). At least one other phr gene product has a role in sporulation. phrA mutants have a sporulation frequency ∼10% of that of wild-type cells, and sporulation can be restored to wild-type levels by addition to the medium of a peptide corresponding to the C-terminal portion of PhrA (Perego and Hoch, 1996). This rescue is dependent on the oligopeptide permease (Spo0K). PhrA is thought to inhibit activity of the phosphatase, RapA, a negative regulator of sporulation (Mueller et al., 1992; Mueller and Sonenshein, 1992; Perego et al., 1994; Perego and Hoch, 1996). It is likely that other Phr products work in a manner similar to that of CSF and PhrA.

Here, we document several aspects of Phr peptide function that are critical to understanding their mode of action. By changing, in turn, each residue of the CSF pentapeptide to alanine, we showed that different residues are required for each of the three activities of CSF, suggesting that CSF has at least three different targets inside the cell. In addition, we demonstrated that CSF can be transported into the cell when present extracellularly at physiologically relevant concentrations (10 nM), and that transport depends on the oligopeptide permease encoded by spo0K (opp). Furthermore, we showed

*Present Address: Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111.

that at least one form of CSF and the PhrA pentapeptide, when expressed from a small gene inside the cell, can function intracellularly. CSF and the PhrA peptide represent an emerging class of cell–cell signaling molecules that are actively imported and function intracellularly.

Results

Effects of Alanine Substitutions on the Activity of CSF

CSF has two distinct effects on expression of *srfA* (Solomon et al., 1996). In wild-type cells, low concentrations of CSF ($\sim$2–10 nM) stimulate expression of *srfA*, while high concentrations of CSF ($\geq$20 nM) inhibit expression of *srfA*. To determine the residues of the CSF pentapeptide required for these activities, we used a series of peptides with each position of CSF changed (one at a time) to alanine. Each peptide was tested for the ability to stimulate or inhibit expression of *srfA*, as judged by accumulation of β-galactosidase from a *srfA–lacZ* fusion.

Each position of CSF was important for stimulation of expression of *srfA*. The alanine-mutant peptides were added to wild-type cells (containing a *srfA–lacZ* fusion) at low cell density, when *srfA–lacZ* expression is low. The wild-type CSF peptide (ERGMT) stimulated expression of *srfA–lacZ* such that β-galactosidase specific activity increased $\sim$3-fold during the time (70 min) of the assay (Figure 1). The peak of activity was at a peptide concentration of $\sim$5 nM, as seen previously (Solomon et al., 1996). In contrast, none of the alanine-mutant peptides stimulated expression of *srfA–lacZ* (Figures 1A–1E), indicating that each position of CSF is important for the inducing activity.

The alanine-mutant peptides were tested for the ability to inhibit *srfA–lacZ* in a *rapC* mutant. The *rapC* mutant was used because it has higher basal levels of expression of *srfA–lacZ*, making it easier to detect inhibition. In addition, *srfA* expression is not stimulated by CSF in a *rapC* mutant (Solomon et al., 1996), eliminating the overlapping regulation that causes stimulation. As expected, wild-type CSF (ERGMT) inhibited expression of *srfA–lacZ* (Figures 2A–2E). The effects of the alanine-mutant peptides were varied (Figure 2). Alanine in the first or third position resulted in little or no change in inhibitory activity, while alanine in the fifth position resulted in reduced, but still significant inhibitory activity. In contrast, the peptides with alanine in the second (arginine) or fourth (methionine) position had little or no inhibitory activity. These results indicate that only the second position, arginine, and the fourth position, methionine, are required for the inhibiting activity of CSF.

The results with the alanine-mutant peptides indicate that there are two different targets of CSF, one contributing to stimulation and a second contributing to inhibition of expression of *srfA*, and these targets recognize different residues in CSF. In wild-type cells, inhibition is observed at $\geq$20 nM CSF, whereas in the *rapC* mutant, inhibition is observed at $\sim$2 nM CSF (compare Figure 1 and Figure 2). At low concentrations, CSF is probably causing inhibition in wild-type cells as well, but the inhibition is masked by the stimulatory activity. Furthermore, the stimulatory activity might be much greater in the absence of the inhibitory effect.

Extracellular Control of Sporulation and CSF

Multiple peptide factors contribute to the extracellular control of sporulation. To detect an effect of *phrC* on sporulation, and to test which positions of CSF are required for stimulation of sporulation, we made use of an allele of *spo0H* that causes a defect in the extracellular control of sporulation (see Experimental Procedures). *spo0H* encodes a sigma factor of RNA polymerase that is essential for sporulation (Stragier and Losick, 1996), and the *ecs191* mutation of *spo0H* causes a defect in production of extracellular sporulation factors (Grossman and Losick, 1988). The sporulation frequency of the *ecs191* mutant ranges from $\sim$10^{-1} to 10^{-4} that of wild type, depending on the cell density at which sporulation is induced (Figure 3). Addition of other cells or conditioned medium rescues the sporulation frequency of the mutant up to $\sim$1%–10% of that of wild type.

phrC and Sporulation

Whereas a *phrC* single mutant has little or no defect in sporulation (Solomon et al., 1996), the *phrC ecs191* double mutant had a sporulation frequency that was 5%–10% of that of the *ecs191* single mutant (Figure 3).


Figure 1. Effects of CSF Alanine-Mutant Peptides on Stimulation of Expression of *srfA*

Cells containing a *srfA–lacZ* fusion (JRL476) were grown in defined minimal medium. At a low cell density, cells were mixed with the indicated amount of peptide and incubated for 70 min at 37°C, and β-galactosidase specific activity was assayed. Open circles indicate wild-type CSF (ERGMT); closed triangles indicate the alanine-mutant peptides. The alanine-mutant peptide is indicated in each panel. (A), ARGMT; (B), EAGMT; (C), ERAMT; (D), ERGAT; and (E), ERGMA.

Figure 2. Effects of CSF Alanine-Mutant Peptides on Inhibition of Expression of *srfA*

rapC mutant cells containing a *srfA–lacZ* fusion (BAL116) were grown and treated as described in Figure 1. Open circles indicate wild-type CSF (ERGMT); closed triangles indicate the alanine-mutant peptides. (A)–(E) are as indicated in Figure 1. The inhibition is not a general effect on β-galactosidase-specific activity: β-galactosidase from other *lacZ* fusions is not affected by high concentrations CSF (data not shown).

The effect of the Δ*phrC* mutation on sporulation was due to the defect in production of extracellular CSF. Addition of 1 μM CSF to the *ecs191 phrC* double mutant resulted in full rescue of the *phrC* defect (Figure 4), and addition of as little as 20 nM resulted in partial rescue. CSF accumulates in the culture medium to levels ≥1 μM at the onset of stationary phase (our unpublished data), indicating that the levels needed for full rescue are physiologically significant.

The extracellular signaling factors involved in sporulation are probably partly redundant, and the phenotype of the *ecs191* mutant is most likely due to defects in production of multiple sporulation factors. Transcription of genes encoding the extracellular factors or genes required for maturation and secretion of the factors is probably reduced due to a defective sigma-H (*spo0H* gene product). It is interesting to note that sigma-H partly controls transcription of *phrC* (Carter et al., 1991), and CSF production is reduced, but not eliminated, in a *spo0H* null mutant (Solomon et al., 1995, 1996). The effect of *spo0H* on production of CSF is only partial, and there is clearly still enough expression so that a null mutation in *phrC* causes a sporulation phenotype in the *ecs191* mutant background.


Figure 3. *phrC* Affects Sporulation in the *ecs191* Mutant Background

Cells were grown in defined minimal medium and induced to sporulate at the indicated density by addition of decoyinine. Closed circles indicate wild type (AG174); open boxes indicate *ecs191* (AG388); and closed triangles indicate *ecs191 phrC* (BAL81). The *phrC* mutation alone causes little or no defect in sporulation (not shown).

CSF Alanine Mutants and Sporulation

Each position of CSF, except the third position glycine, was needed for stimulation of sporulation. Each of the mutant peptides was added at a concentration of 1 μM to the *ecs191 phrC* double mutant, and the ability to stimulate sporulation was measured (Figure 4). Whereas wild-type CSF stimulated sporulation ∼40-fold, the alanine-mutant peptides had greatly reduced activity, except for the third position glycine-to-alanine mutant. The glycine-to-alanine mutant peptide (ERAMT) consistently stimulated sporulation to higher levels than the wild-type peptide (ERGMT).

It is clear that the residues of CSF needed to stimulate sporulation are different from those needed to inhibit expression of *srfA* (Figure 2). The regulatory factors required to inhibit expression of *srfA* and to stimulate sporulation are not known, but our results indicate that the two processes are distinct. Taken together, the effects of the alanine-mutant peptides on stimulation and inhibition of expression of *srfA*, and on stimulation of sporulation, strongly suggest that CSF interacts with at least three different targets to affect gene expression and development.

CSF Is Transported into the Cell at the Low Concentrations Needed for Signaling

The oligopeptide permease encoded by *spo0K* (*opp*) is required for the cells to respond to CSF (Solomon et al., 1995, 1996). A simple model is that the oligopeptide permease transports CSF into the cell and the peptide interacts with intracellular targets. Alternatively, the oligopeptide permease could function as a receptor and uptake of CSF would not be important for signaling. There is precedent for ATP-dependent importers functioning as receptors to control signaling pathways (Cox et al., 1988; Wanner, 1993). There is no doubt that the oligopeptide permease is able to import CSF (ERGMT). Cells can utilize CSF (Solomon et al., 1996) and PhrA (our unpublished data), as well as many other oligopeptides (Mathiopoulos et al., 1991; Perego et al., 1991; Koide and Hoch, 1994) (our unpublished data), to satisfy an amino acid auxotrophy, and utilization depends on the

Figure 4. Effects of CSF Alanine-Mutant Peptides on Sporulation of the *ecs191 phrC* Mutant

The *ecs191 phrC* double mutant (BAL81) was grown in defined minimal medium to an optical density (600 nm) of ~0.2 and induced to sporulate by the addition of decoyinine in the presence of the indicated peptide. Peptides were added to a concentration of 1 μM. The Gly-to-Ala mutant peptide (ERAMT) consistently stimulated sporulation to higher levels than the wild-type peptide (ERGMT).

Figure 5. Expression of the CSF Ala1 Peptide, (M)ARGMT, inside the Cell Inhibits Expression of *srfA*

rapC phrC mutant strains (BAL68, BAL69, and BAL59) containing a *srfA–lacZ* fusion and one of three different multicopy plasmids (pDG148, pBL3, and pBL4, respectively) were grown in minimal medium. IPTG (1 mM) was added at an optical density (600 nm) of ~0.05 to induce transcription from the Pspac promoter on each plasmid. Samples were taken for determination of β-galactosidase-specific activity at the indicated densities. Closed circles indicate pDG148 (cloning vector); open triangles indicate pBL3 [*icpC*, encoding the CSF Ala1 peptide (M)ARGMT]; and open boxes indicate pBL4 [*icpA*, encoding the PhrA peptide (M)ARNQT].

oligopeptide permease. However, the concentrations of peptide used to support growth of an auxotroph are in the mM range, much greater than the concentration required for the regulatory responses (~2 nM to 1 μM). Therefore, we wished to determine if the oligopeptide permease was able to transport CSF into the cell when the peptide was present in the nM concentration range.

At an external CSF concentration of 10 nM, cells were able to import CSF via the Spo0K oligopeptide permease. When radiolabeled CSF (10 nM) was added to a *phrC* null mutant (unable to produce CSF), it was taken up at an initial rate of ~5 pmol per min per mg of cell protein (see Experimental Procedures). This corresponds to approximately 2,000 molecules of CSF per min per cell. A *spo0K* (*opp*) null mutant had no detectable uptake ($<10^{-3}$ pmol peptide per min per mg protein). This dependence on the oligopeptide permease is consistent with its requirement for cell growth on mM amounts of CSF (Solomon et al., 1996). To show that the peptide was actually transported into the cell and not simply associating with the cell surface, we showed that uptake was dependent on ATP. Transport via the ABC importers is sensitive to azide (a respiratory chain inhibitor) due to depletion of ATP (Parnes and Boos, 1973; Berger and Heppel, 1974). Uptake of radiolabeled CSF (10 nM) by cells treated with azide (see Experimental Procedures) was not detectable ($<10^{-3}$ pmol peptide per min per mg protein).

Phr Peptides Can Function Intracellularly
Given that CSF is transported into the cell by the oligopeptide permease, we wished to determine if CSF actually has intracellular targets, and if CSF can function inside the cell. In addition, we wished to determine if a second Phr peptide, PhrA, also could function inside the cell. To test for intracellular function, we constructed two small genes (*icp* genes), each encoding an intracellular peptide (see Experimental Procedures). Each gene

contains a ribosome binding site and an initiation codon, and is fused to the LacI-repressible, IPTG-inducible promoter Pspac. *icpC* encodes MARGMT, which corresponds to the CSF peptide with an alanine in place of glutamate and the necessary initiator methionine. *icpA* encodes MARNQT, which corresponds to the PhrA peptide plus the initiator methionine. Formyl-methionine (f-met) followed by alanine should result in removal of the f-met, leaving ARGMT (CSF Ala1) and ARNQT (PhrA pentapeptide) inside the cell.

The ARGMT peptide is a mutant version of CSF that is able to inhibit, but not stimulate, expression of *srfA* (Figures 1A and 2A). Use of this peptide was necessary because f-met is not expected to be removed from wild-type CSF, and neither MERGMT nor MRGMT functions to stimulate or inhibit expression of *srfA* when added exogenously to cells (data not shown).

CSF Ala1
The CSF Ala1 peptide was able to function inside the cell. We measured expression of *srfA–lacZ* in a *rapC phrC* mutant as a function of cell density (Figure 5). When the peptide encoded by *icpC*, (M)ARGMT, was induced inside the cell by the addition of IPTG, *srfA–lacZ* expression was inhibited (Figure 5). This inhibition was most dramatic at relatively low cell density, when expression of *srfA–lacZ* begins to be induced. As cells grow to higher density and approach stationary phase, accumulation of β-galactosidase-specific activity reaches that of the control cells. Induction of Pspac transcription in cells containing the vector had little or no effect on expression of *srfA–lacZ* (Figure 5). To confirm that the ability to inhibit expression of *srfA* is not a general consequence of production of any comparable intracellular peptide, we tested the effect of producing the IcpA peptide, (M)ARNQT, inside the cell. Expression of the IcpA peptide did not inhibit expression of *srfA* (Figure 5). We do not yet know what proteins are required for the inhibiting activity of CSF, but these data indicate that

Figure 6. Expression of the PhrA Peptide inside the Cell Rescues the Sporulation Defect of a *phrA* Mutant

Cells were grown in nutrient sporulation medium in the absence (−) or presence (+) of IPTG (1 mM). Cells contained either the cloning vector (pDG148) or the plasmid with *icpA* (pBL3). IPTG was added during the early exponential phase of growth (OD$_{600}$ ∼0.1). Strains were wild type with the cloning vector, pDG148 (KI2006), the *phrA* mutant with the cloning vector (BAL74), and the *phrA* mutant with the Pspac-*ipcA* plasmid encoding (M)ARNQT, pBL3 (BAL75).

CSF interacts with an intracellular target to inhibit *srfA* expression, and that target is not RapC.

PhrA Pentapeptide

The PhrA peptide is also able to function inside the cell. *phrA* mutants are defective in sporulation and can be rescued by adding extracellular peptides that correspond to the C-terminal portion of the PhrA precursor protein (Perego and Hoch, 1996). A peptide that corresponds to the last 5 amino acids of PhrA, ARNQT, functions most efficiently for rescue of the sporulation defect of a *phrA* mutant (data not shown). The 5 amino acid peptide is active at approximately one-tenth of the concentration of a peptide that corresponds to the C-terminal 6 amino acids of the PhrA precursor (data not shown). Therefore, we asked if the defect in sporulation of a *phrA* mutant could be rescued intracellularly by the IcpA peptide, (M)ARNQT. When expression of *icpA* was induced with IPTG, the level of sporulation in the *phrA* mutant was restored to that of the congenic wild-type strain (Figure 6).

To test if the *icp* products were getting out of the cell and functioning extracellularly, we tested culture supernatant from strains expressing *icpC* and *icpA* for peptide activity. The culture supernatant from the *icpC* strain was not able to inhibit expression of *srfA*, nor was the supernatant from the *icpA* strain able to rescue the sporulation defect of a *phrA* mutant (data not shown). As an additional control, we verified that we would have detected activity had the peptides been in the culture supernatant. We added ARGMT (CSF Ala1) to the *icpC* culture supernatant and ARNQT (PhrA pentapeptide) to the *icpA* culture supernatant and tested for activity under the appropriate conditions. Each peptide was able to function when mixed with the culture supernatant from the *icp* strain (data not shown). Based on these results, we conclude that CSF and the PhrA pentapeptide can function inside the cell. It seems likely that other Phr peptides also function inside the cell.

Discussion

Our results indicate that the extracellular signaling peptides, CSF and PhrA, are actively transported into the cell and interact with intracellular receptors. CSF interacts with multiple intracellular receptors, resulting in different physiological responses at different concentrations of the peptide. Because it is secreted, CSF serves as a signal for high population density, one of the conditions that regulates initiation of competence development and sporulation. CSF accumulates extracellularly to concentrations necessary to elicit a physiological response as cells in culture grow to high density. Response to extracellular peptides that are transported back into the cell represents an emerging mechanism for cell–cell signaling, involving active import of a signaling molecule and subsequent interaction with an intracellular receptor.

CSF and the PhrA peptide are produced from secreted precursors, the *phrC* and *phrA* gene products, that are 40 and 44 amino acid peptides, respectively, each with a signal sequence (Perego and Hoch, 1996; Solomon et al., 1996). The mature form of CSF is a pentapeptide that accumulates in the culture medium (Solomon et al., 1996). The mature form of PhrA that accumulates in the culture medium has not been identified directly, but we propose that the mature extracellular form of PhrA is a also a pentapeptide. The mechanism for processing the secreted precursors to the mature pentapeptides is not known, but may happen during secretion in the membrane or on the cell surface.

At least two other putative *phr* genes have been identified based on their size and location adjacent to and downstream from a *rap* gene (Perego et al., 1996). Completion of the B. subtilis genome sequencing project may allow identification of additional *phr* genes. A function has not been ascribed to these *phr* gene products, but they probably encode secreted peptides that mediate regulation of cellular processes by cell–cell signaling. The production of multiple Phr peptides by B. subtilis indicates that multiple processes are probably regulated by cell–cell signaling, that different peptides might be produced under different growth conditions, and/or that there is considerable redundancy in signaling.

Intracellular Targets of the Phr Peptides

At least one target of CSF and the PhrA peptide appears to be the cognate Rap phosphatase encoded upstream of *phrC* and *phrA*, respectively (Perego et al., 1996; Solomon et al., 1996). These peptides may bind directly to the Rap phosphatase inhibiting its activity, or to an unidentified target that inhibits the activity of the Rap phosphatase.

CSF has at least two additional intracellular targets. The proteins required for CSF to inhibit *srfA* expression or stimulate sporulation have not been identified, but our results with the alanine-mutant peptides indicate that the targets required for stimulating sporulation and inhibiting expression of *srfA* in response to CSF are not the same. We speculate that the inhibition of *srfA* expression by CSF might be due to inhibition of the autokinase activity (or stimulation of a potential phosphatase activity) of ComP, the histidine protein kinase

required for phosphorylation of ComA and subsequent activation of transcription of *srfA*. CSF probably affects sporulation by affecting the level of Spo0A~P, the key transcription factor required for initiation of sporulation (Hoch, 1993; Grossman, 1995). Constitutively active forms of Spo0A bypass the requirement for high cell density and extracellular spore factors for efficient sporulation (Ireton et al., 1993). CSF could increase the level of Spo0A~P by inhibiting the activity of a Rap phosphatase that dephosphorylates Spo0A~P or a component of the phosphorelay that activates Spo0A.

The Role of the Oligopeptide Permease in B. subtilis
Our results show that CSF is transported into the cell at concentrations that are physiological relevant for cell–cell signaling, and that transport depends on the oligopeptide permease encoded by *spo0K* (*opp*). The oligopeptide permease is able to import CSF at the lowest concentrations we tested, 2 nM. It seems likely that the PhrA peptide is also imported via the oligopeptide permease, as *spo0K* is required for cells to respond to the PhrA pentapeptide (our unpublished data). Thus, one role of the oligopeptide permease for competence and sporulation is to import the CSF and PhrA signaling peptides.

The *spo0K* null mutants cause competence and sporulation defects that are more severe than simply the absence of CSF and/or PhrA, indicating an additional role for the oligopeptide permease. This additional role could be in controlling other Rap phosphatases that normally do not affect competence or sporulation, but that might be hyperactive in a *spo0K* null mutant (the "phosphatase run amok" model). In addition, the oligopeptide permease might interact directly with one or more of the Rap phosphatases, or other intracellular receptors, to facilitate inhibition of phosphatase activity by the Phr peptides. Consistent with the notion that the developmental defect of a *spo0K* mutant is more than simply inability to transport CSF and the PhrA peptides, we found that expression of the IcpA (PhrA pentapeptide) inside the cell did not fully suppress the sporulation defect of a *spo0K* (*opp*) null mutant (our unpublished

data). It may be possible to obtain altered function mutations in *spo0K* that affect response to some peptides but not others, and to begin to dissect the different roles of the oligopeptide permease in development.

Mechanisms for Cell–Cell Signaling
Mechanisms for responding to cell–cell signaling molecules generally have been divided into two types: (1) interaction of the signaling molecule with a membrane-associated receptor and transmembrane signaling, and (2) passive diffusion of the signaling molecule across the membrane to interact with an intracellular receptor. Examples of signaling molecules that interact (or are thought to interact) with a membrane receptor include mating pheromones of Saccharomyces cerevisiae (Kurjan, 1992; Herskowitz, 1995), the ComX pheromone of B. subtilis (Magnuson et al., 1994; Solomon et al., 1995), the competence pheromone of Streptococcus pneumoniae (Håvarstein et al., 1995; Håvarstein et al., 1996; Pestova et al., 1996), and the AgrD peptide pheromone of Staphylococcus aureus (Ji et al., 1995). All of these signaling molecules activate a membrane-bound receptor, and in the bacterial examples, the receptor is a histidine kinase that autophosphorylates and donates phosphate to a cognate transcription factor. Cell–cell signaling molecules that passively diffuse across the membrane and interact with an intracellular receptor exist in both eukaryotes and prokaryotes. The steroid hormones interact with intracellular transcription factors to regulate gene expression (Tsai and O'Malley, 1994). Quorum sensing in many gram-negative bacteria involves diffusion of the signaling molecule, an acyl-homoserine lactone, into the cell and interaction with an intracellular receptor, usually a transcription factor of the LuxR family (Fuqua et al., 1996).

A third mechanism for responding to cell–cell signaling molecules is emerging in prokaryotes, as illustrated by the mechanism of responding to the Phr peptides of B. subtilis. In contrast to the two mechanisms described above, the extracellular Phr peptides of B. subtilis must interact with two proteins: an importer to actively transport the signaling molecule into the cell, and a second

Table 1. B. subtilis Strains

Strains	Relevant Genotype [comments]
AG174 (JH642)	*trpC2, pheA1*
AG388	*spo0HT106I* [*ecs191*]
BAL59	*amy*::(*srfA-lacZΩ1974 cat*::*spc*) *rapC*::pJS49 [*cat*] Δ*phrC*::*erm* pBL3 [*neo*]
BAL68	*amy*::(*srfA-lacZΩ1974 cat*::*spc*) *rapC*::pJS49 [*cat*] Δ*phrC*::*erm* pDG148 [*neo*]
BAL69	*amy*::(*srfA-lacZΩ1974 cat*::*spec*) *rapC*::pJS49 [*cat*] Δ*phrC*::*erm* pBL4 [*neo*]
BAL74	*phrA*::pBL1 [*cat*] pDG148 [*neo*]
BAL75	*phrA*::pBL1 [*cat*] pBL3 [*neo*]
BAL81	*spo0HT106I* [*ecs191*] Δ*phrC*::*erm*
BAL101	*phrA*::pBL1 [*cat*]
BAL116	*amy*::(*srfA-lacZΩ1974 cat*::*spec*) *rapC*::pJS49 [*cat*][b]
JMS751	Δ*phrC*::*erm*
JMS753	*amy*::(*srfA-lacZΩ1974 cat*::*spc*) Δ*phrC*::*erm*[b]
JMS754	*amy*::(*srfA-lacZΩ1974 cat*::*spc*) Δ*phrC*::*erm* Δ*spo0K*::*neo*
JMS763	*amy*::(*srfA-lacZΩ1974 cat*::*spc*) *rapC*::pJS49 [*cat*] Δ*phrC*::*erm*
JRL476	*amy*::(*srfA-lacZΩ1974 cat*::*spc*)[a,b]

[a] Magnuson et al., 1994.
[b] Solomon et al., 1996.

intracellular receptor to cause a change in gene expression. Several other signaling molecules in prokaryotes also appear to be transported into the cell by an active mechanism. These often include peptides that are taken up by an oligopeptide permease. In addition to Phr peptides of B. subtilis, the mating pheromones of Enterococcus faecalis appear to be taken up by an oligopeptide permease (Leonard et al., 1996). Competence regulation in S. pneumoniae is modulated by several oligopeptide binding proteins and an oligopeptide permease. While these are not required for response to the major competence pheromone, they do play a role in modulating competence and suggest a possible role for additional peptide signals during competence development in S. pneumoniae (Pearce et al., 1994; Alloing et al., 1996). Development of aerial mycelium in Streptomyces coelicolor also requires an oligopeptide permease, suggesting that an extracellular signaling peptide(s) is required for development (Nodwell et al., 1996). It seems likely that these other signaling molecules function similarly to the Phr peptides of B. subtilis, with import required for interaction of the signaling molecule with an intracellular receptor. Expressing mature forms of the signaling molecules inside the cell could be generally useful in dissecting signaling mechanisms and signal transduction pathways. Considering the ubiquitous nature of ABC transporters (Higgins, 1992), the combined use of such a transporter and an intracellular receptor for response to cell–cell signaling molecules may prove to be widespread.

Experimental Procedures

Construction of Plasmids Containing *icpC* and *icpA*
Standard cloning and sequencing techniques were used (Ausubel et al., 1990). For each *icp* gene, two oligonucleotides were synthesized (Integrated DNA Technologies) that were complimentary except for 5′ HindIII and 3′ SphI sticky ends. The oligonucleotides for *icpC* contained 18 bp upstream of the start of *phrC* and encoded the peptide MARGMT and a stop codon. The two IcpC oligonucleotides with the restriction site sticky ends in bold and the amino acid coding sequence underlined were: 5′-**AGCTT**AAAGGAGTGAAGGTT TGT<u>ATGGCAAGAGGAATGACG</u>TAA**GCATG**-3′ and the complimentary 3′-**A**TTTCCTCACTTCCAAACA<u>TACCGTTCTCCTTACTGC</u>TT**C**-5′.

Similarly, the oligonucleotides for *icpA* contained 18 bp upstream of the start of *phrA* and encoded the peptide MARNQT and a stop codon. The IcpA oligonucleotides, with bold and underlined bases as above, were: 5′-**AGCTT**AGAGAGGAGATTGTTTAT<u>ATGGCACGC AATCAAAC</u>ATGA-3′ and the complimentary 3′-**A**TCTCTCCTCTAA CAAATA<u>TACCGTGCGTTAGTTTG</u>TACT-5′.

Equimolar amounts of the complimentary Icp oligonucleotides were mixed, heated to 70°C, and annealed during slow cooling to room temperature. The annealed oligonucleotides were ligated into the HindIII–SphI vector fragment of pDG148 (Stragier et al., 1988), resulting in the *icp* genes under control of the LacI-repressible, IPTG-inducible promoter, Pspac (Yansura and Henner, 1984). pBL4 is pDG148 with *icpC*, and pBL3 is pDG148 with *icpA*. The inserts were confirmed by DNA sequencing.

B. subtilis Strains
B. subtilis strains are derivatives of AG174 (JH642, *trpC*, *pheA*) unless indicated otherwise. Strains and relevant genotypes are listed in Table 1. Standard procedures were used for transformations and strain constructions (Harwood and Cutting, 1990). The *srfA–lacZ* fusion (Hahn et al., 1994; Magnuson et al., 1994) was integrated into the chromosome at the *amyE* locus. Integration of pBL1 into the B. subtilis chromosome by single crossover resulted in disruption of *phrA*, as described (Perego and Hoch, 1996). pBL1 contains the 614

bp EcoRI–BsiEI fragment from pJPM74 (Mueller et al., 1992), that is internal to the *rapA phrA* operon cloned into pJH101 (Ferrari et al., 1983). Multicopy plasmids pDG148, pBL3, and pBL4 were transformed into B. subtilis selecting for resistance to neomycin. Antibiotics were used at the following concentrations: chloramphenicol, 5 μg/ml; neomycin, 5 μg/ml; phleomycin, 0.5 μg/ml; erythromycin and lincomycin together at 0.5 μg/ml and 12.5 μg/ml, respectively.

β-Galactosidase Assays and the Effect of CSF on *srfA* Expression
Cells were grown in defined minimal medium with glucose (1%) and glutamate (0.1%) and required amino acids (40 μg/ml), as previously described (Jaacks et al., 1989; Magnuson et al., 1994; Solomon et al., 1995, 1996). When necessary, antibiotics were included to maintain selection for plasmids. β-galactosidase-specific activity is presented as (ΔA_{420} per min per ml of culture per OD_{600}) × 1000 (Miller, 1972; Jaacks et al., 1989; Magnuson et al., 1994). To measure the effect of exogenously added CSF on *srfA* expression, β-galactosidase-specific activity was measured after incubating 0.25 ml of cells at low cell density (OD_{600} ∼0.1) with 0.25 ml of CSF peptide (at indicated concentrations) for 70 min at 37°C as previously described (Solomon et al., 1995, 1996).

Sporulation Assays
Cells grown in defined minimal medium with glucose and glutamate and induced to sporulate by the addition of decoyinine (U-7984; Upjohn Co.) to 500 μg/ml. Decoyinine is an inhibitor of GMP synthetase and induces sporulation by causing a drop in intracellular GTP (Mitani et al., 1977). Alternatively, cells were grown in nutrient sporulation medium (Harwood and Cutting, 1990) and sporulation was induced upon entry into stationary phase. Sporulation was measured 18–20 hr after induction as the number of colony forming units (CFU) per ml after heat treatment (80°C for 20 min) as a fraction of the total number of CFU per ml before heat treatment (Harwood and Cutting, 1990).

Isolation and Characterization of *ecs191*, a Mutant Defective in the Extracellular Control of Sporulation
The rationale for the mutant hunt was based on that used for the isolation of mutants defective in extracellular signaling in Myxococcus xanthus (Hagen et al., 1978). Briefly, mutants were identified that were defective in sporulation, but that were stimulated to sporulate in the presence of other cells or in the presence of conditioned medium (culture supernatant) from other cells.

B. subtilis strain KS306 (prototroph, *cotA*::Tn*917*) (Donovan et al., 1987; Sandman et al., 1987) was mutagenized with nitrosoguanidine (Miller, 1972) and allowed to sporulate in nutrient sporulation medium. Any mutant defective in the extracellular control of sporulation should be stimulated to sporulate due to the presence of mostly Spo+ cells in the mutagenized culture. After enough time for sporulation, the culture was subjected to heat killing (80°C for 15 min), lysozyme treatment (1 mg/ml for 60 min at 37°C), and then another heat treatment (80°C for 15 min). The surviving spores were then diluted and spread on sporulation plates containing the indicator XP, and excess phosphate to prevent induction of the vegetative alkaline phosphatase. Colonies that appeared to be defective in production of the sporulation-associated alkaline phosphatase, as indicated by lack of blue color, were chosen for further study. The *cotA* mutant was used to facilitate visualization of the presence of alkaline phosphatase. *cotA* encodes a spore coat protein that is responsible for the dark brown color of sporulating colonies, and the *cotA* mutant produces colonies lacking the brown spore pigment (Donovan et al., 1987).

Candidate mutants that appeared to be defective in sporulation as isolated colonies on solid sporulation medium were chosen for further analysis. Candidates were tested in liquid medium for the ability to sporulate in pure culture, or in the presence of other cells, typically a *spoIIA* mutant that produces normal amounts of extracellular sporulation factors, but is blocked at stage II of sporulation and produces <10 spores/ml. The mutant with the strongest phenotype, *ecs191*, was stimulated to sporulate ∼100-fold in the presence of the *spoIIA* mutant cells, or in the presence of conditioned medium.

The mutation causing the phenotype was backcrossed into unmutagenized cells by unlinked cotransformation (congression). Strain AG232 (*sigB*::*cat dal*) was transformed to *dal*[+] on nutrient sporulation plates in the absence of D-alanine. Transformants that also became Spo[−] were chosen and retested in liquid culture for the ability to be rescued extracellularly. Strain AG388 is an isolate that contained the *ecs191* mutation. In nutrient sporulation medium, the *ecs191* mutant has a sporulation frequency ∼0.1% of wild type, and this defect is rescued ∼10- to 100-fold in the presence of other cells. *ecs191* was mapped by transduction and transformation using standard procedures (Harwood and Cutting, 1990) and found to be an allele of *spo0H*. Cloning and DNA sequence analysis indicated that *ecs191* caused a change from threonine to isoleucine at amino acid 106 of sigma-H, the *spo0H* gene product, a sigma factor of RNA polymerase (Stragier and Losick, 1996).

Peptide Synthesis

Nonradioactive peptides were purchased from Genmed Biotechnologies (So. San Francisco, CA). Radioactive CSF (ERGMT) was synthesized with ^{3}H-glycine (Dupont NEN). Met-Thr dipeptide (10 μmol) was synthesized on an Advanced Chemtech MPS-350 automated peptide synthesizer. ^{3}H-glycine (5 mCi; 98 nmol) was N-terminally blocked with 9-fluoromethyl chloroformate (fmoc) by the micropreparation protocol essentially as described (Moye and Boning, 1979), except that the fmoc-^{3}H-Gly was used directly in the peptide synthesis, without purification. fmoc-^{3}H-Gly was coupled to the Met-Thr peptide. The remaining (excess) Met-Thr was coupled to fmoc-Lys, creating a mixture of tripeptides ^{3}H-GMT and KMT. After addition of the Arg and Glu residues, the radioactive ERGMT pentapeptide was separated from ERKMT by HPLC chromatography in the MIT Biopolymers Laboratory.

Peptide Transport

Strains JMS753 (*phrC*) and JMS754 (*phrC spo0K*) were used to measure the rate of uptake of radiolabeled CSF (ERGMT). Cells were grown in defined minimal media to an optical density (600 nm) of ∼1. Cells were removed from medium by centrifugation, washed twice, and resuspended in minimal salts (medium lacking a carbon source and amino acids) in one fifth of their original volume. Radiolabeled peptide was added to cells at room temperature to the desired final concentration, 2 or 10 nM. Aliquots (0.1 ml) were removed every 10 sec after the addition of the peptide, filtered over a 0.45 μ HA filter (Millipore), and washed with 10 ml of minimal medium lacking carbon or amino acids. Filters were counted in a Beckman LS 6000 scintillation counter.

Using the specific activity of the ^{3}H-glycine (51.1 mCi/nmol), the amount of ERGMT peptide taken up per min per mg of cellular protein or per cell was determined. The concentration of cellular protein from lysed cells was determined using the Bio-Rad Protein Assay Kit and BSA as a standard. The cells were diluted and plated on LB to determine the number of cells used in the experiment. In a typical experiment, the amount of ERGMT taken up versus time was linear during the first two minutes, and the rate of uptake was determined from these early time points.

Import by the ABC transporters is sensitive to azide due to ATP depletion. To show that uptake of ERGMT was ATP dependent, cells were washed as above and treated with the respiratory chain inhibitor sodium azide (10 mM) for 1 hr at 37°C, prior to adding the radioactive peptide (Parnes and Boos, 1973; Berger and Heppel, 1974).

Acknowledgments

References

Alloing, G., Granadel, C., Morrison, D.A., and Claverys, J.-P. (1996). Competence pheromone, oligopeptide permease, and induction of competence in *Streptococcus pneumoniae*. Mol. Microbiol. *21*, 471–478.

Ausubel, F., Brent, R., Kingston, R., Moore, D., Seidman, J., Smith, J. and Struhl, K. (1990). Current Protocols in Molecular Biology. (New York, NY: John Wiley and Sons).

Berger, E.A., and Heppel, L.A. (1974). Different mechanisms of energy coupling for the shock-sensitive and shock-resistant amino acid permeases of *Escherichia coli*. J. Biol. Chem. *249*, 7747–7755.

Cangelosi, G.A., Ankenbauer, R.G., and Nester, E.W. (1990). Sugars induce the *Agrobacterium* virulence genes through a periplasmic binding protein and a transmembrane signal protein. Proc. Natl. Acad. Sci. USA *87*, 6708–6712.

Carter, H.L., III, Tatti, K.M., and Moran, C.P., Jr. (1991). Cloning of a promoter used by sigma-H RNA polymerase in *Bacillus subtilis*. Gene *96*, 101–105.

Cox, G.B., Webb, D., Godovac-Zimmermann, J., and Rosenberg, H. (1988). Arg-220 of the PstA protein is required for phosphate transport through the phosphate-specific transport system in *Escherichia coli* but not for alkaline phosphatase repression. J. Bacteriol. *170*, 2283–2286.

Donovan, W., Zheng, L., Sandman, K., and Losick, R. (1987). Genes encoding spore coat polypeptides from *Bacillus subtilis*. J. Mol. Biol. *196*, 1–10.

Ferrari, F.A., Nguyen, A., Lang, D., and Hoch, J.A. (1983). Construction and properties of an integrable plasmid for *Bacillus subtilis*. J. Bacteriol. *154*, 1513–1515.

Fuqua, C., Winans, S.C., and Greenberg, E.P. (1996). Census and consensus in bacterial ecosystems: the LuxR-LuxI family of quorum-sensing transcriptional regulators. Annu. Rev. Microbiol. *50*, 727–751.

Grossman, A.D. (1995). Genetic networks controlling the initiation of sporulation and the development of genetic competence in *Bacillus subtilis*. Annu. Rev. Genet. *29*, 477–508.

Grossman, A.D., and Losick, R. (1988). Role of extracellular factors in the control of sporulation in *Bacillus subtilis*. In Genetics and Biotechnology of Bacilli, Volume 2, A.T. Ganesan and J.A. Hoch, eds. (San Diego, CA: Academic Press), pp. 175–179.

Hagen, D.C., Bretscher, A.P., and Kaiser, D. (1978). Synergism between morphogenetic mutants of *Myxococcus xanthus*. Dev. Biol. *64*, 284–296.

Hahn, J., Kong, L., and Dubnau, D. (1994). The regulation of competence transcription factor synthesis constitutes a critical control point in the regulation of competence in *Bacillus subtilis*. J. Bacteriol. *176*, 5753–5761.

Harwood, C.R., and Cutting, S.M. (1990). Molecular Biological Methods for *Bacillus*. (Chichester, England: John Wiley and Sons).

Håvarstein, L.S., Coomaraswamy, G., and Morrison, D. (1995). An unmodified heptadecapeptide pheromone induces competence for genetic transformation in *Streptococcus pneumoniae*. Proc. Natl. Acad. Sci. USA *92*, 11140–11144.

Håvarstein, L.S., Gaustad, P., Nes, I.F., and Morrison, D.A. (1996). Identification of the streptococcal competence-pheromone receptor. Mol. Microbiol. *21*, 863–869.

Herskowitz, I. (1995). MAP kinase pathways in yeast: for mating and more. Cell *80*, 187–197.

Higgins, C.F. (1992). ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. *8*, 67–113.

Hoch, J.A. (1993). Regulation of the phosphorelay and the initiation of sporulation in *Bacillus subtilis*. Annu. Rev. Microbiol. *47*, 441–465.

Hoch, J.A., and Silhavy, T.J. (1995). Two-component signal transduction. (Washington, D.C.: ASM Press).

Ireton, K., Rudner, D.Z., Siranosian, K.J., and Grossman, A.D. (1993). Integration of multiple developmental signals in *Bacillus subtilis* through the Spo0A transcription factor. Genes Dev. *7*, 283–294.

Jaacks, K.J., Healy, J., Losick, R., and Grossman, A.D. (1989). Identification and characterization of genes controlled by the sporulation regulatory gene *spo0H* in *Bacillus subtilis*. J. Bacteriol. *171*, 4121–4129.

Ji, G., Beavis, R.C., and Novick, R.P. (1995). Cell density control of staphylococcal virulence mediated by an octapeptide pheromone. Proc. Natl. Acad. Sci. USA *92*, 12055–12059.

Koide, A., and Hoch, J.A. (1994). Identification of a second oligopeptide transport system in *Bacillus subtilis* and determination of its role in sporulation. Mol. Microbiol. *13*, 417–426.

Kurjan, J. (1992). Pheromone response in yeast. Annu. Rev. Biochem. *61*, 1097–1129.

Leonard, B.A.B., Podbielski, A., Hedberg, P.J., and Dunny, G.M. (1996). *Enterococcus faecalis* pheromone binding protein, PrgZ, recruits a chromosomal oligopeptide permease system to import sex pheromone cCF10 for induction of conjugation. Proc. Natl. Acad. Sci. USA *93*, 260–264.

Magnuson, R., Solomon, J. and Grossman, A.D. (1994). Biochemical and genetic characterization of a competence pheromone from B. subtilis. Cell *77*, 207–216.

Manson, M.D., Blank, V., Brade, G., and Higgins, C.F. (1986). Peptide chemotaxis in E. coli involves the Tap signal transducer and the dipeptide permease. Nature *321*, 253–256.

Mathiopoulos, C., Mueller, J.P., Slack, F.J., Murphy, C.G., Patankar, S., Bukusoglu, G., and Sonenshein, A.L. (1991). A *Bacillus subtilis* dipeptide transport system expressed early during sporulation. Mol. Micribiol. *5*, 1903–1913.

Miller, J. (1972). Experiments in Molecular Genetics. (Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory).

Mitani, T., Heinze, J.F., and Freese, E. (1977). Induction of sporulation in *Bacillus subtilis* by decoyinine or hadacidin. Biochem. Biophys. Res. Commun. *77*, 1118–1125.

Moye, H.A., and Boning, A.J.J. (1979). A versatile fluorogenic labelling reagent for primary and secondary amines: 9-fluorenylmethyl chloroformate. Anal. Lett. *12*, 25–35.

Mueller, J.P., Bukusoglu, G., and Sonenshein, A.L. (1992). Transcriptional regulation of *Bacillus subtilis* glucose starvation-inducible genes: control of *gsiA* by the ComP-ComA signal transduction system. J. Bacteriol. *174*, 4361–4373.

Mueller, J.P., and Sonenshein, A.L. (1992). Role of the *Bacillus subtilis gsiA* gene in regulation of early sporulation gene expression. J. Bacteriol. *174*, 4374–4383.

Nakano, M.M., Xia, L., and Zuber, P. (1991). Transcription initiation region of the *srfA* operon, which is controlled by the ComP-ComA signal transduction system in *Bacillus subtilis*. J. Bacteriol. *173*, 5487–5493.

Nakano, M.M., and Zuber, P. (1989). Cloning and characterization of *srfB*, a regulatory gene involved in surfactin production and competence in *Bacillus subtilis*. J. Bacteriol. *171*, 5347–5353.

Nakano, M.M., and Zuber, P. (1991). The primary role of ComA in establishment of the competent state in *Bacillus subtilis* is to activate expression of *srfA*. J. Bacteriol. *173*, 7269–7274.

Nodwell, J.R., McGovern, K., and Losick, R. (1996). An oligopeptide permease responsible for the import of an extracellular signal governing aerial mycelium formation in *Streptomyces coelicolor*. Mol. Microbiol. *22*, 881–893.

Parkinson, J.S., and Kofoid, E.C. (1992). Communication modules in bacterial signaling proteins. Annu. Rev. Genet. *26*, 71–112.

Parnes, J.R., and Boos, W. (1973). Energy coupling of the β-methyl-galactoside transport system of *Escherichia coli*. J. Biol. Chem. *248*, 4429–4435.

Pearce, B.J., Naughton, A.M., and Masure, H.R. (1994). Peptide permeases modulate transformation in *Streptococcus pneumoniae*. Mol. Microbiol. *12*, 881–892.

Perego, M., Glaser, P., and Hoch, J.A. (1996). Aspartyl-phosphate phosphatases deactivate the response regulator components of the sporulation signal transduction system in *Bacillus subtilis*. Mol. Microbiol. *19*, 1151–1157.

Perego, M., Hanstein, C., Welsh, K.M., Djavakhishvili, T., Glasser, P., and Hoch, J.A. (1994). Multiple protein-aspartate phosphatases provide a mechanism for the integration of diverse signals in the control of development in B. subtilis. Cell *79*, 1047–1055.

Perego, M., Higgins, C.F., Pearce, S.R., Gallagher, M.P., and Hoch, J.A. (1991). The oligopeptide transport system of *Bacillus subtilis* plays a role in the initiation of sporulation. Mol. Microbiol. *5*, 173–185.

Perego, M., and Hoch, J.A. (1996). Cell–cell communication regulates the effects of protein aspartate phosphatases on the phosphorelay controlling development in *Bacillus subtilis*. Proc. Natl. Acad. Sci. USA *93*, 1549–1553.

Pestova, E.V., Håvarstein, L.S., and Morrison, D.A. (1996). Regulation of competence for genetic transformation in *Streptococcus pneumoniae* by an auto-induced peptide pheromone and a two-component regulatory system. Mol. Microbiol. *21*, 853–862.

Roggiani, M., and Dubnau, D. (1993). ComA, a phosphorylated response regulator protein of *Bacillus subtilis*, binds to the promoter region of *srfA*. J. Bacteriol. *175*, 3182–3187.

Rudner, D.Z., LeDeaux, J.R., Ireton, K., and Grossman, A.D. (1991). The *spo0K* locus of *Bacillus subtilis* is homologous to the oligopeptide permease locus and is required for sporulation and competence. J. Bacteriol. *173*, 1388–1398.

Sandman, K., Losick, R., and Youngman, P. (1987). Genetic analysis of *Bacillus subtilis spo* mutations generated by Tn*917*-mediated insertional mutagenesis. Genetics *117*, 603–617.

Solomon, J.M., and Grossman, A.D. (1996). Who's competent and when: regulation of natural genetic competence in bacteria. Trends Genet. *12*, 150–155.

Solomon, J.M., Lazazzera, B.A., and Grossman, A.D. (1996). Purification and characterization of an extracellular peptide factor that affects two different developmental pathways in *Bacillus subtilis*. Genes Dev. *10*, 2014–2024.

Solomon, J.M., Magnuson, R., Srivastava, A., and Grossman, A.D. (1995). Convergent sensing pathways mediate response to two extracellular competence factors in *Bacillus subtilis*. Genes Dev. *9*, 547–558.

Stragier, P., Bonamy, C., and Karmazyn-Campelli, C. (1988). Processing of a sporulation sigma factor in *Bacillus subtilis*: how morphological structure could control gene expression. Cell *52*, 697–704.

Stragier, P., and Losick, R. (1996). Molecular genetics of sporulation in *Bacillus subtilis*. Annu. Rev. Genet. *30*, 297–341.

Tsai, M.-J., and O'Malley, B.W. (1994). Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. *63*, 451–486.

Wanner, B.L. (1993). Gene regulation by phosphate in enteric bacteria. J. Cell. Biochem. *51*, 47–54.

Weinrauch, Y., Guillen, N., and Dubnau, D. (1989). Sequence and transcription mapping of *Bacillus subtilis* competence genes *comB* and *comA*, one of which is related to a family of bacterial regulatory determinants. J. Bacteriol. *171*, 5362–5375.

Weinrauch, Y., Penchev, R., Dubnau, E., Smith, I., and Dubnau, D. (1990). A *Bacillus subtilis* regulatory gene product for genetic competence and sporulation resembles sensor protein members of the bacterial two-component signal-transduction systems. Genes Dev. *4*, 860–872.

Yansura, D.G., and Henner, D.J. (1984). Use of the *Escherichia coli lac* repressor and operator to control gene expression in *Bacillus subtilis*. Proc. Natl. Acad. Sci. USA *81*, 439–443.